Sponsored Supplement

Challenges, Evidence, and Treatment Options for Anticoagulation of Obese and Morbidly Obese Patients with Nonvalvular Atrial Fibrillation (NVAF)

Publish date: January 23, 2020
Sponsored by Janssen Pharmaceuticals, Inc.

 

In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include:

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

Next Article:

Actor Alan Alda discusses using empathy as an antidote to burnout